{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:26:51Z","timestamp":1780370811544,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012393"],"award-info":[{"award-number":["2021A1515012393"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["CX23303"],"award-info":[{"award-number":["CX23303"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371692"],"award-info":[{"award-number":["82371692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["21623311"],"award-info":[{"award-number":["21623311"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jbo.2024.100601","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:46:17Z","timestamp":1713325577000},"page":"100601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Reversine inhibits proliferation and induces apoptosis of human osteosarcoma cells through targeting MEK1"],"prefix":"10.1016","volume":"46","author":[{"given":"Xianlong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeyin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2537-5752","authenticated-orcid":false,"given":"Xuesong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2024.100601_b0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/07357907.2020.1768401","article-title":"Epidemiology and risk factors of osteosarcoma","volume":"38","author":"Sadykova","year":"2020","journal-title":"Cancer Invest."},{"key":"10.1016\/j.jbo.2024.100601_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102684","article-title":"Osteosarcoma in adolescents and young adults","volume":"10","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jbo.2024.100601_b0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/annonc\/mdu526","article-title":"EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment","volume":"26","author":"Whelan","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2024.100601_b0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2010.11.036","article-title":"Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials","volume":"47","author":"Gelderblom","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2024.100601_b0025","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/sj.cdd.4401958","article-title":"Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle","volume":"13","author":"Anastasia","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jbo.2024.100601_b0030","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/1535-7163.MCT-07-2051","article-title":"Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells","volume":"7","author":"D'Alise","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jbo.2024.100601_b0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1083\/jcb.201001036","article-title":"Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine","volume":"190","author":"Santaguida","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jbo.2024.100601_b0040","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/prot.25174","article-title":"Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase","volume":"84","author":"Hiruma","year":"2016","journal-title":"Proteins"},{"key":"10.1016\/j.jbo.2024.100601_b0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10565-016-9333-1","article-title":"Some leopards can change their spots: Potential repositioning of stem cell reprogramming compounds as anti-cancer agents","volume":"32","author":"Kim","year":"2016","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.jbo.2024.100601_b0050","first-page":"1293","article-title":"The 2,6-disubstituted purine reversine induces growth arrest and polyploidy in human cancer cells","volume":"31","author":"Hsieh","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbo.2024.100601_b0055","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2021.12871","article-title":"Targeting glioma cells by antineoplastic activity of reversine","volume":"22","author":"Hirakata","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jbo.2024.100601_b0060","doi-asserted-by":"crossref","first-page":"e10637","DOI":"10.7717\/peerj.10637","article-title":"Reversine, a selective MPS1 inhibitor, induced autophagic cell death via diminished glucose uptake and ATP production in cholangiocarcinoma cells","volume":"9","author":"Prajumwongs","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.jbo.2024.100601_b0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/21655979.2021.2009410","article-title":"Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2","volume":"13","author":"Zhang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.jbo.2024.100601_b0070","first-page":"153","article-title":"Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions","volume":"22","author":"Pearson","year":"2001","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jbo.2024.100601_b0075","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.jbo.2024.100601_b0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/1541-7786.MCR-20-0687","article-title":"The MEK\/ERK network as a therapeutic target in human cancer","volume":"19","author":"Barbosa","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jbo.2024.100601_b0085","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12026-010-8187-5","article-title":"Role of Ras\/Raf\/MEK\/ERK signaling in physiological hematopoiesis and leukemia development","volume":"49","author":"Chung","year":"2011","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jbo.2024.100601_b0090","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: The long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbo.2024.100601_b0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12957-022-02510-8","article-title":"Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells","volume":"20","author":"Hou","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.jbo.2024.100601_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10654-019-00576-5","article-title":"A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research","volume":"35","author":"Muka","year":"2020","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.jbo.2024.100601_b0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jbo.2024.100601_b0110","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbo.2024.100601_b0115","doi-asserted-by":"crossref","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","article-title":"STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data","volume":"44","author":"Szklarczyk","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbo.2024.100601_b0120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nbt1284","article-title":"Relating protein pharmacology by ligand chemistry","volume":"25","author":"Keiser","year":"2007","journal-title":"Nat. Biotechnol."},{"issue":"2023","key":"10.1016\/j.jbo.2024.100601_b0125","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbo.2024.100601_b0130","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein-ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jbo.2024.100601_b0135","doi-asserted-by":"crossref","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbo.2024.100601_b0140","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"2018","key":"10.1016\/j.jbo.2024.100601_b0145","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jbo.2024.100601_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105684","article-title":"Advances in targeted therapy for osteosarcoma based on molecular classification","volume":"169","author":"Chen","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jbo.2024.100601_b0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12282-012-0400-z","article-title":"Reversine induces cell cycle arrest, polyploidy, and apoptosis in human breast cancer cells","volume":"21","author":"Kuo","year":"2014","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jbo.2024.100601_b0160","first-page":"733","article-title":"Reversine triggers mitotic catastrophe and apoptosis in BCR-ABL positive cells","volume":"101","author":"Alves","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jbo.2024.100601_b0165","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2147\/OTT.S158198","article-title":"Reversine, a substituted purine, exerts an inhibitive effect on human renal carcinoma cells via induction of cell apoptosis and polyploidy","volume":"11","author":"Cheng","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jbo.2024.100601_b0170","doi-asserted-by":"crossref","first-page":"e0158587","DOI":"10.1371\/journal.pone.0158587","article-title":"Reversine induced multinucleated cells, cell apoptosis and autophagy in human non-small cell lung cancer cells","volume":"11","author":"Lu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jbo.2024.100601_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CAD.0000000000000563","article-title":"Reversine induces autophagic cell death through the AMP-activated protein kinase pathway in urothelial carcinoma cells","volume":"29","author":"Fang","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jbo.2024.100601_b0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1423-0127-19-9","article-title":"Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy","volume":"19","author":"Lee","year":"2012","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jbo.2024.100601_b0185","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopha.2012.08.001","article-title":"Autophagy induction of reversine on human follicular thyroid cancer cells","volume":"66","author":"Lu","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jbo.2024.100601_b0190","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/bjc.2013.675","article-title":"Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine","volume":"109","author":"Bijian","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2024.100601_b0195","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1007\/s11095-012-0727-3","article-title":"Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells","volume":"29","author":"Hua","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jbo.2024.100601_b0200","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1038\/ncomms6662","article-title":"Resolving cancer-stroma interfacial signalling and interventions with micropatterned tumour-stromal assays","volume":"5","author":"Shen","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbo.2024.100601_b0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jbo.2024.100601_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2021.104136","article-title":"Reversine suppresses osteosarcoma cell growth through targeting BMP-Smad1\/5\/8-mediated angiogenesis","volume":"135","author":"Hu","year":"2021","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.jbo.2024.100601_b0215","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s13258-019-00790-1","article-title":"Reversine induces caspase-dependent apoptosis of human osteosarcoma cells through extrinsic and intrinsic apoptotic signaling pathways","volume":"41","author":"Kim","year":"2019","journal-title":"Genes Genomics"},{"key":"10.1016\/j.jbo.2024.100601_b0220","doi-asserted-by":"crossref","first-page":"10482","DOI":"10.1073\/pnas.0704360104","article-title":"Reversine increases the plasticity of lineage-committed mammalian cells","volume":"104","author":"Chen","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.jbo.2024.100601_b0225","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jbo.2024.100601_b0230","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jbo.2024.100601_b0235","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-5113","article-title":"Activation of the RAF\/mitogen-activated protein\/extracellular signal-regulated kinase Kinase\/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma","volume":"14","author":"Yang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2024.100601_b0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.canlet.2007.02.013","article-title":"1alpha,25-Dihydroxyvitamin D3 antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1\/p21waf1 upregulation in human osteosarcoma","volume":"254","author":"Wu","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbo.2024.100601_b0245","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jcb.22631","article-title":"Ganglioside GD1a Suppression of NOS2 Expression Via ERK1 Pathway in Mouse Osteosarcoma FBJ Cells","volume":"110","author":"Cao","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jbo.2024.100601_b0250","first-page":"356","article-title":"GD1a activatesMAPKpathway via calciumsignaling to suppress NOS2 expression in mouse osteosarcoma cells in an EGFR-independent manner","volume":"30","author":"Yang","year":"2013","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.jbo.2024.100601_b0255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00280-002-0502-y","article-title":"Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines","volume":"50","author":"Woessmann","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jbo.2024.100601_b0260","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12013-013-9781-7","article-title":"VEGFR, RET, and RAF\/MEK\/ERK Pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment","volume":"69","author":"Mei","year":"2014","journal-title":"Cell Biochem. Biophys."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:30:43Z","timestamp":1769416243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137424000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":52,"alternative-id":["S2212137424000812"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100601","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversine inhibits proliferation and induces apoptosis of human osteosarcoma cells through targeting MEK1","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100601"}}